頭頸部扁平上皮癌における新たな診断・治療標的

This review aims to explore the evolving field of theranostics in oncology, focusing on its potential application to head and neck squamous cell carcinoma (HNSCC). Specifically, it examines the integration of molecular imaging and radionuclide therapy in the context of theranostics.A comprehensive review of current literature was conducted to evaluate the state-of-the-art theranostic approaches in HNSCC. The review includes an analysis of established and emerging molecular targets relevant to HNSCC, as well as the potential for future theranostic developments.The integration of theranostic principles into head and neck oncology is gaining momentum, with increasing interest in novel targets in the context of theranostics. Although [¹⁸F]FDG PET/CT still remains the dominant imaging modality in HNSCC, the application of novel radiotracers for imaging and radionuclide therapy holds considerable promise.Theranostics represents a promising future for head and neck oncology, offering the potential for personalized, biology-driven diagnostic and therapeutic strategies. While many emerging approaches are still under investigation, the combination of molecular imaging and targeted radionuclide therapy may significantly enhance the treatment of HNSCC, providing more precise and effective patient care in the future.1.